Ocera Therapeutics (OCRX) 2.28 $OCRX Ocera Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ocera Therapeutics (OCRX) 2.28 $OCRX

Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update
GlobeNewswire - Wed Aug 03, 3:17PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended June 30, 2016, and provided updates on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a debilitating liver disorder and significant burden on the healthcare system.
OCRX: 2.28 (+0.23)

Ocera to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Jefferies 2016 Healthcare Conference. Ocera's presentation will take place on Friday, June 10, 2016 at 11:30 AM Eastern Time.
OCRX: 2.28 (+0.23)

Ocera to Present at the 2016 BIO International Convention
GlobeNewswire - Thu May 26, 3:05PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D., Chief Business Officer, will be presenting at the 2016 BIO International Convention being held at the Moscone Center in San Francisco, California from June 6-9, 2016. Ocera's presentation will take place on Wednesday, June 8, 2016 in Room 1 at 1:00 PM Pacific Time.
OCRX: 2.28 (+0.23)

Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress
GlobeNewswire - Fri Apr 29, 8:05AM CDT
-- Company on target to complete enrollment in STOP-HE in the fourth quarter; approximately 165 patients enrolled to date --
OCRX: 2.28 (+0.23)

Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)
GlobeNewswire - Fri Apr 15, 8:05AM CDT
Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosis
OCRX: 2.28 (+0.23)

Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
GlobeNewswire - Mon Apr 11, 8:05AM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the publication of promising preclinical data related to the Company's investigational drug candidate ornithine phenylacetate, OCR-002. The paper, entitled "Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension" is published in the April 2016 issue of the Journal of Hepatology (http://www.journal-of-hepatology.eu/article/S0168-8278(15)00777-1/abstract).
OCRX: 2.28 (+0.23)

Ocera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:25PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the 15 Annual Needham Healthcare Conference being held at The Westin NY Grand Central Hotel in New York, New York from April 12-13, 2016. Ocera's presentation will take place on Wednesday, April 13, 2016 at 3:40 PM Eastern Time.
OCRX: 2.28 (+0.23)

LifeSci Capital Initiates Coverage of Ocera Therapeutics
ACCESSWIRE - Thu Mar 24, 8:58AM CDT
Developing Therapies for Serious Diseases with High Unmet Medical Need; Report Available Here: http://www.lifescicapital.com/equity-research/ocera/
OCRX: 2.28 (+0.23)

Ocera to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 3:20PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18 Annual BIO CEO & Investor Conference taking place February 8 - 9, 2016 at the Waldorf Astoria in New York, NY. Ocera's management will present at 10:00 AM ET on Tuesday, February 9, in the Conrad room in the conference's Orphan/Rare Diseases track.
OCRX: 2.28 (+0.23)

3 Sectors to Avoid as China Stock Market Takes a Bumpy Ride
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 3:53PM CST
This time not only did the Chinese investors suffer -- stakeholders all over the world felt the heat of this market slump.
ALNY: 69.17 (+0.15), BVN: 13.90 (+0.73), OCRX: 2.28 (+0.23), IPI: 1.40 (+0.01), MIND: 2.78 (-0.03), HELI: 3.67 (-0.33)

Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
GlobeNewswire - Fri Jan 08, 8:05AM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced further details from its Phase 1 study of oral formulations of OCR-002, ornithine phenylacetate, in healthy subjects. The Company plans to conduct additional Phase 1 testing after further formulation optimization.
OCRX: 2.28 (+0.23)

Ocera names Dr Stan Bukofzer as CMO
M2 - Fri Jan 08, 6:09AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Thursday the addition of Dr Stan Bukofzer as its chief medical officer.
OCRX: 2.28 (+0.23)

Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer
GlobeNewswire - Thu Jan 07, 3:05PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Dr. Stan Bukofzer as Chief Medical Officer. Dr. Bukofzer most recently served as Chief Medical Officer of Hospira, Inc., where he was responsible for providing strategic and operational direction for clinical development, pharmacovigilance and safety and medical affairs across Hospira's three business units.
OCRX: 2.28 (+0.23)

A Refreshing Outlook -- Comprehensive Research on AU Optronics, Ocera Therapeutics, Solar3D and SUPERVALU
ACCESSWIRE - Tue Dec 22, 7:28AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: AU Optronics Corp (NYSE: AUO), Ocera Therapeutics Inc. (NASDAQ: OCRX), Solar3D Inc. (NASDAQ: SLTD) and SUPERVALU Inc. (NYSE: SVU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AUO: 3.73 (-0.04), SVU: 5.72 (+0.21), OCRX: 2.28 (+0.23), SLTD: 2.44 (+0.01)

Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
GlobeNewswire - Mon Nov 16, 3:05PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced positive results from the Company's Phase 1 study of the oral formulation of OCR-002, ornithine phenylacetate, in healthy subjects. OCR-002 exhibited encouraging extended-release properties, demonstrated a desirable pharmacokinetic (PK) profile and was well-tolerated.
OCRX: 2.28 (+0.23)

Ocera to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Mon Nov 09, 3:06PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that Gaurav Aggarwal, M.D., chief business officer, will be presenting at the Stifel 2015 Healthcare Conference being held at The New York Palace Hotel in New York, NY November 17-18, 2015. Ocera's presentation will take place in the Spellman Room on Tuesday, November 17 at 4:30 PM Eastern Time.
OCRX: 2.28 (+0.23)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 50

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 168

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 202

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 153

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Conrad Industries Reports Strong Third Quarter Financial Growth

Updated Category News Views 393

Conrad Industries Announces Third Quarter 2024 Financial Results Conrad Industries, Inc. (OTC Pink: CNRD) recently shared its financial performance for the third quarter ending September 30, 2024. The company reported a net income of $7.5 million, translating to earnings per diluted share of $1.49. This marks a significant turnaround from the third quarter of 2023, which...

Continue Reading
CytoSorbents Webinar Aims to Combat Sepsis and Septic Shock

Updated Category News Views 129

Understanding the Impact of Sepsis and Septic Shock Sepsis and septic shock pose serious threats in critical healthcare settings. Each year, millions of people are affected by these life-threatening conditions. Recognizing the need for innovative solutions, CytoSorbents Corporation has been at the forefront, utilizing its proprietary blood purification technologies to...

Continue Reading
Summa Defence Plc Updates Shareholding Structure Details

Updated Category News Views 271

Overview of Recent Notifications by Summa Defence Plc Summa Defence Plc has made important announcements relating to their shareholding structure and corporate governance, underscoring the dynamic nature of stockholder engagement. These events reflect the ongoing changes in ownership percentages that can significantly impact their operational strategy. Notification of...

Continue Reading
Quantifind's AI Tech Earns High Marks in Compliance

Updated Category News Views 17

Quantifind among the Industry's Top Innovators Well, here's a name to watch: Quantifind. Recognized as a Top 10 technology provider in financial crime and compliance, this Palo Alto-based firm is making waves. Our friends over at Chartis seem to think highly of them, and they don't toss out accolades willy-nilly. So, what's Quantifind doing that's so special? Pioneering...

Continue Reading
Dolby Laboratories Posts Strong Q1 Results with Promising Growth

Updated Category News Views 164

Strong Start for Dolby Laboratories in FY 2026 Dolby Laboratories, Inc. (NYSE: DLB) recently shared its financial results for the first quarter of fiscal 2026, showcasing promising developments despite the challenging market landscape. The company remains optimistic about its position and future growth opportunities. Kevin Yeaman, President and CEO of Dolby, expressed...

Continue Reading